Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $211.65 | Total: $1,058.25 |
| 1 | 10 | $179.28 | Total: $1,792.80 |
| 1 | 25 | $151.89 | Total: $3,797.25 |
| 1 | 50 | $129.48 | Total: $6,474.00 |
| 1 | 100 | $112.05 | Total: $11,205.00 |
Overview
LY 517717 is an orally active inhibitor of coagulation factor Xa with antithrombotic activity for the study of venous thromboembolism (VTE).
Chemical Properties
| Molecular Formula | C27H33N5O2 |
| Molecular Weight | 459.58 |
| CAS Numbers | 313489-71-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | [C@@H](C(=O)N1CCN(CC1)C2CCN(C)CC2)(NC(=O)C=3C=C4C(=CC3)C=CN4)C5=CC=CC=C5 |
Storage and Handling
0C Short Term, -20C Long Term
References
Agnelli G, et al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost. 2007 Apr;5[4] 746-53.